Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy

PURPOSE: Docetaxel + cisplatin + 5-fluorouracil (DCF) therapy, a frequently prescribed regimen for esophageal cancer, is associated with a high risk of febrile neutropenia (FN). This study investigated whether a low skeletal muscle mass index (SMI) is an independent risk factor for FN. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Nara, Katsuhiko, Yamamoto, Takehito, Sato, Yasuyoshi, Yagi, Koichi, Kawasaki, Koichiro, Toriumi, Tetsuro, Takada, Tappei, Seto, Yasuyuki, Suzuki, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898323/
https://www.ncbi.nlm.nih.gov/pubmed/36737558
http://dx.doi.org/10.1007/s00520-023-07609-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898323/
https://www.ncbi.nlm.nih.gov/pubmed/36737558
http://dx.doi.org/10.1007/s00520-023-07609-6

Ejemplares similares